PNC Financial Services Group Inc. Raises Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

PNC Financial Services Group Inc. grew its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 893.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,245 shares of the specialty pharmaceutical company’s stock after acquiring an additional 86,560 shares during the quarter. PNC Financial Services Group Inc. owned about 0.17% of Jazz Pharmaceuticals worth $9,599,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Signaturefd LLC lifted its position in shares of Jazz Pharmaceuticals by 106.3% in the first quarter. Signaturefd LLC now owns 260 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 134 shares in the last quarter. North Star Investment Management Corp. purchased a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at $28,000. CI Investments Inc. lifted its position in shares of Jazz Pharmaceuticals by 846.2% in the fourth quarter. CI Investments Inc. now owns 246 shares of the specialty pharmaceutical company’s stock valued at $37,000 after acquiring an additional 220 shares in the last quarter. Trustcore Financial Services LLC lifted its position in shares of Jazz Pharmaceuticals by 52.6% in the fourth quarter. Trustcore Financial Services LLC now owns 290 shares of the specialty pharmaceutical company’s stock valued at $43,000 after acquiring an additional 100 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its position in shares of Jazz Pharmaceuticals by 966.7% in the fourth quarter. Quadrant Capital Group LLC now owns 384 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 348 shares in the last quarter. Institutional investors and hedge funds own 91.10% of the company’s stock.

Several equities analysts recently weighed in on the company. Jefferies Financial Group assumed coverage on Jazz Pharmaceuticals in a research report on Monday, April 6th. They set a “buy” rating and a $149.00 target price on the stock. Piper Sandler dropped their price target on Jazz Pharmaceuticals from $127.00 to $113.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Oppenheimer restated a “buy” rating and set a $132.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. SVB Leerink dropped their price target on Jazz Pharmaceuticals from $169.00 to $160.00 and set an “outperform” rating for the company in a research note on Wednesday, May 6th. Finally, Cowen lowered their target price on Jazz Pharmaceuticals from $200.00 to $165.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $155.26.

In other Jazz Pharmaceuticals news, VP Patricia Carr sold 247 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $119.75, for a total transaction of $29,578.25. Following the transaction, the vice president now owns 8,153 shares of the company’s stock, valued at approximately $976,321.75. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Finbar Larkin sold 279 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $119.75, for a total value of $33,410.25. Following the transaction, the senior vice president now directly owns 14,790 shares in the company, valued at approximately $1,771,102.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,333 shares of company stock worth $471,855. 4.30% of the stock is currently owned by company insiders.

Shares of NASDAQ JAZZ opened at $110.85 on Friday. Jazz Pharmaceuticals PLC has a fifty-two week low of $86.88 and a fifty-two week high of $154.24. The business has a 50 day moving average price of $108.64 and a two-hundred day moving average price of $129.14. The company has a quick ratio of 3.62, a current ratio of 3.83 and a debt-to-equity ratio of 0.61. The firm has a market cap of $6.13 billion, a PE ratio of 9.82, a price-to-earnings-growth ratio of 1.27 and a beta of 1.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.24. Jazz Pharmaceuticals had a return on equity of 21.66% and a net margin of 12.81%. The company had revenue of $534.73 million for the quarter, compared to the consensus estimate of $544.55 million. During the same quarter last year, the business posted $3.67 EPS. Jazz Pharmaceuticals’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post 9.82 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: What is the Ex-Dividend Date in Investing?

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.